Multicomponent T2 analysis (mcT2) can provide a clinically-useful myelin biomarker in vivo. Its clinical applicability, however, is hindered by lack of gold standard technique that can overcome the ambiguity of fitting several T2 components to a single experimental signal. In this study we aimed to validate the utility of a novel data-driven mcT2 mapping algorithm for quantifying myelin content. To that end, we applied the mcT2 algorithm to 14 mice divided into two groups of mice: cuprizone-induced demyelination model, and controls. Results show excellent agreement between the mcT2 based myelin biomarker and ground truth quantification of myelin from immunohistochemical staining.